David Kirske - Sep 29, 2022 Form 4 Insider Report for CTI BIOPHARMA CORP (CTIC)

Role
EVP, Chief Financial Officer
Signature
David Kirske
Stock symbol
CTIC
Transactions as of
Sep 29, 2022
Transactions value $
-$718,991
Form type
4
Date filed
10/3/2022, 06:26 PM
Previous filing
Sep 20, 2022
Next filing
Oct 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTIC common stock Options Exercise $759 +800 +4.73% $0.95 17.7K Sep 29, 2022 Direct
transaction CTIC common stock Sale -$4.8K -800 -4.52% $6.00 16.9K Sep 29, 2022 Direct F1
transaction CTIC common stock Options Exercise $94.90 +100 +0.59% $0.95 17K Sep 29, 2022 Direct
transaction CTIC common stock Sale -$601 -100 -0.59% $6.01 16.9K Sep 29, 2022 Direct F1
transaction CTIC common stock Options Exercise $133K +140K +826.83% $0.95 157K Sep 30, 2022 Direct
transaction CTIC common stock Sale -$846K -140K -89.21% $6.05 16.9K Sep 30, 2022 Direct F1, F2
transaction CTIC common stock Options Exercise $285 +300 +1.77% $0.95 17.2K Oct 3, 2022 Direct
transaction CTIC common stock Sale -$1.88K -300 -1.74% $6.25 16.9K Oct 3, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -800 -0.17% $0.00 467K Sep 29, 2022 Common Stock 800 $0.95 Direct F3
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -100 -0.02% $0.00 467K Sep 29, 2022 Common Stock 100 $0.95 Direct F3
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -140K -29.98% $0.00 327K Sep 30, 2022 Common Stock 140K $0.95 Direct F3
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -300 -0.09% $0.00 326K Oct 3, 2022 Common Stock 300 $0.95 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F3 One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.